DermaSensor
About DermaSensor
DermaSensor Inc. is a Miami-based medical device company at the forefront of AI-powered skin cancer detection, specifically designed to empower primary care physicians (PCPs) with advanced diagnostic capabilities. The company’s flagship product, the DermaSensor™ device, is an FDA-cleared, non-invasive, handheld tool that leverages cutting-edge optical spectroscopy and artificial intelligence to evaluate suspicious skin lesions for potential malignancy in seconds. This technology works by emitting light bursts onto a lesion and analyzing the scattered light spectra to detect properties consistent with malignancy at a cellular and subcellular level, akin to an ultrasound but using light.
The DermaSensor device provides an objective 0-10 cancer risk assessment scale, guiding physicians with ‘Investigate Further’ or ‘Monitor’ recommendations. It is indicated for use by non-dermatologist physicians to assess lesions concerning for melanoma, basal cell carcinoma (BCC), and squamous cell carcinoma (SCC) in patients 40 years or older. Clinical studies have demonstrated that the device significantly improves PCPs’ ability to detect skin cancer, increasing management sensitivity and diagnostic sensitivity, and reducing false negative referrals. By offering rapid, accurate, and objective assessments at the point of care, DermaSensor aims to bridge the gap in dermatology access, streamline the skin exam process, and ultimately facilitate earlier detection and intervention for skin cancer, which is crucial for improved patient outcomes.
Focus Areas
Business Intelligence
| Key Investors | Pier 70 Ventures, Kern Venture Group, GenHenn Capital, SternAegis Ventures, Ceros Capital Markets, Miami Angels, Harmonix, Ligo Partners, Serial Stage Venture Partners, David Matlin, Chris Dewey |
| Partnerships | Mayo Clinic, Yale University, University of North Carolina School of Medicine, SUNY Downstate Health Sciences University (for clinical studies) |
| Technology | Elastic Scattering Spectroscopy (ESS), AI algorithms, machine learning, optical spectroscopy, handheld device, cloud integration |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
DermaSensor stands out for physicians by offering an objective, non-invasive, and rapid tool to enhance skin cancer detection in primary care settings. It significantly improves a primary care physician's (PCP) ability to evaluate suspicious lesions, with studies showing increased sensitivity for melanoma detection and a reduction in missed skin cancers. The device provides objective data on cellular and sub-cellular structures, augmenting visual inspection and dermoscopy, which can lead to more confident and appropriate referral decisions to dermatology. This is particularly valuable in addressing the existing gaps in access to dermatological care, allowing PCPs to play a more proactive role in early skin cancer identification and patient triage. Its ease of use and quick results integrate seamlessly into busy clinical workflows, ultimately aiming to improve patient outcomes through earlier detection and timely intervention.
The DermaSensor device is a handheld, wireless unit designed for point-of-care use. It features cloud-based data synchronization via a secure Wi-Fi connection for software updates and remote device functionality monitoring. While the search results do not explicitly detail direct EMR/EHR integrations, its design emphasizes seamless integration into existing clinical workflows within various practice types, including family medicine and internal medicine.
What the Web Says
DermaSensor is a health technology company that has developed an AI-powered, handheld device designed to assist primary care physicians (PCPs) in evaluating skin lesions for potential cancer. The device uses elastic scattering spectroscopy and a machine-learning algorithm to provide objective information, aiming to improve early detection and reduce the rate of missed skin cancers. While it has received FDA clearance and shows high sensitivity in detecting various skin cancers, its low specificity means it may flag a significant number of benign lesions, potentially leading to unnecessary referrals.
Overall: PositiveStrengths
- High sensitivity in detecting skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma.
- Increases diagnostic and referral sensitivity for PCPs, helping them identify high-risk lesions.
- Improves physician confidence in management decisions regarding suspicious lesions.
- Non-invasive and easy to use, requiring minimal training.
- Can help bridge gaps in access to dermatology by empowering PCPs.
- Works effectively across different skin tones.
Limitations
- Low specificity, meaning a notable percentage of benign lesions may be flagged as potentially malignant, leading to unnecessary biopsies or referrals.
- Requires a WiFi connection to perform screenings.
- Additional expense due to a subscription-based plan.
- Not practical for general lesion screening due to time/steps involved.
- Cost-effectiveness remains uncertain.
- One employee review mentioned not being paid for work and issues with accommodating medical needs.
Based on reviews from: TIME, Dermatoscopes.com, Salary.com, HCPLive, Isomer (ACE BRIEF), EINPresswire.com, Reddit, DermaSensor (Official Website), Nature (npj Digital Medicine), Indeed.com, Zippia
Last updated: 2026-07-17
Videos
News, demos, and interviews about DermaSensor.
Videos load interactively. If none appear, search YouTube for DermaSensor →
Press & Coverage
Frequently Asked Questions
Related Companies
QuickIntell is an AI-first healthcare technology company dedicated to transforming healthcare operations for physicians and healthcare providers. The company leverages advanced AI agents, including Computer Vision, Machine Learning, Optical Character Recognition (OCR), and Natural Language Processing (NLP), to streamline administrative workflows and enhance Revenue Cycle Management (RCM). QuickIntell’s solutions are designed to reduce administrative burden, […]
Ease Tax Relief, founded in 2016, is a tax relief and resolution company based in Harleysville, PA. The company specializes in helping individuals and small businesses resolve issues with the IRS, offering services such as Offer in Compromise, Partial Pay Installment Agreements, Payment Plans, and Penalty Reduction. Owned and operated by Zheng Yang, a CPA […]
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]